SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic…
$12.9 Million in Cash and Investments as of September 30, 2023;Runway Expected to Reach Meaningful Development Milestones On Track to…
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ----…
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating…
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on…
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP,…
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of…
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) --…
Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of…
Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple…